Literature DB >> 11172294

A distinct expression of CC chemokines by macrophages in nasopharyngeal carcinoma: implication for the intense tumor infiltration by T lymphocytes and macrophages.

K F Tang1, S Y Tan, S H Chan, S M Chong, K S Loh, L K Tan, H Hu.   

Abstract

Nasopharyngeal carcinoma (NPC) is characterized by harboring Epstein-Barr virus genes in the tumor cells and an intense infiltration of leukocytes in the tumor tissue. These infiltrating cells are mainly composed of T lymphocytes and macrophages. The mechanism of this intense infiltration has long been a puzzle. We attempted to address this issue by studying the expression of CC chemokines, which are responsible for recruiting both T cells and macrophages, by an immunohistochemical approach. In biopsies obtained from nasopharynx of 17 NPC patients that contained tumor cells, expression of macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, macrophage chemoattractant protein-1 (MCP-1), MCP-2, MCP-3, and RANTES was detected in the tumor-infiltrating cells, with MIP-1alpha and MCP-1 found in nearly all biopsies and the others relatively less frequently. Furthermore, expression of interferon-gamma (IFN-gamma) was also observed in tumor-infiltrating cells. In contrast, CC chemokines and IFN-gamma were rarely expressed in the 13 control biopsies that were either normal or with nonspecific inflammation, and in 4 biopsies from untreated NPC patients that contained no tumor cells. Using an immunofluorescent double-staining method, MIP-1alpha and MCP-1 were identified to be associated with macrophages, and IFN-gamma with T cells. Moreover, expression of CCR2 and CCR5, the receptors for these chemokines, was also detected in the tumor-infiltrating cells. These data indicate that the intense tumor infiltration by T cells and macrophages is a result of active recruitment. It seems possible that the intense infiltration of leukocytes in NPC tumor tissue is initiated by the activated tumor-reactive T cells. T cells migrate into the tumor tissue in an antigen-specific mode, and IFN-gamma secreted from these pioneer T cells activates tissue macrophages to express CC chemokines, especially MIP-1alpha and MCP-1, which consequently recruit more T cells and macrophages into the tumor tissue.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11172294     DOI: 10.1053/hupa.2001.20886

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  24 in total

1.  In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin.

Authors:  Catherine Pioche-Durieu; Cécile Keryer; Sylvie Souquère; Jacques Bosq; Wolfgang Faigle; Damarys Loew; Mitsuomi Hirashima; Nozomu Nishi; Jaap Middeldorp; Pierre Busson
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

2.  Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to Toll-like receptor 3-mediated apoptosis.

Authors:  Luc Friboulet; Catherine Pioche-Durieu; Sandrine Rodriguez; Alexander Valent; Sylvie Souquère; Hugues Ripoche; Abdelmajid Khabir; Sai Wah Tsao; Jacques Bosq; Kwok Wai Lo; Pierre Busson
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

3.  Epstein-Barr virus lytic transactivator Zta enhances chemotactic activity through induction of interleukin-8 in nasopharyngeal carcinoma cells.

Authors:  Meichi Hsu; Shih-Yi Wu; Shih-Shin Chang; Ih-Jen Su; Ching-Hwa Tsai; Siao-Jing Lai; Ai-Li Shiau; Kenzo Takada; Yao Chang
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

4.  Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation.

Authors:  Sophia Bornstein; Ruth White; Stephen Malkoski; Masako Oka; Gangwen Han; Timothy Cleaver; Douglas Reh; Peter Andersen; Neil Gross; Susan Olson; Chuxia Deng; Shi-Long Lu; Xiao-Jing Wang
Journal:  J Clin Invest       Date:  2009-10-19       Impact factor: 14.808

5.  Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients.

Authors:  W K Yip; M A Abdullah; S M Yusoff; H F Seow
Journal:  Clin Exp Immunol       Date:  2009-03       Impact factor: 4.330

6.  Monocyte chemoattractant protein 1 and CD40 ligation have a synergistic effect on vascular endothelial growth factor production through cyclooxygenase 2 upregulation in gastric cancer.

Authors:  Seiji Futagami; Atsushi Tatsuguchi; Tetsuro Hiratsuka; Tomotaka Shindo; Akane Horie; Tatsuhiko Hamamoto; Nobue Ueki; Masafumi Kusunoki; Kazumasa Miyake; Katya Gudis; Taku Tsukui; Choitsu Sakamoto
Journal:  J Gastroenterol       Date:  2008-03-29       Impact factor: 7.527

7.  Lymphocyte deficiency limits Epstein-Barr virus latent membrane protein 1 induced chronic inflammation and carcinogenic pathology in vivo.

Authors:  Adele Hannigan; Asif M Qureshi; Colin Nixon; Penelope M Tsimbouri; Sarah Jones; Adrian W Philbey; Joanna B Wilson
Journal:  Mol Cancer       Date:  2011-02-03       Impact factor: 27.401

8.  Expression of indoleamine 2,3-dioxygenase in nasopharyngeal carcinoma impairs the cytolytic function of peripheral blood lymphocytes.

Authors:  Peng Liu; Bai-Lu Xie; Shao-Hui Cai; Yun-Wen He; Ge Zhang; Yan-Mei Yi; Jun Du
Journal:  BMC Cancer       Date:  2009-11-30       Impact factor: 4.430

9.  Toll-like receptor 3 in Epstein-Barr virus-associated nasopharyngeal carcinomas: consistent expression and cytotoxic effects of its synthetic ligand poly(A:U) combined to a Smac-mimetic.

Authors:  Benjamin Vérillaud; Mélanie Gressette; Yannis Morel; Carine Paturel; Philippe Herman; Kwok Wai Lo; Sai Wah Tsao; Michel Wassef; Anne-Sophie Jimenez-Pailhes; Pierre Busson
Journal:  Infect Agent Cancer       Date:  2012-12-03       Impact factor: 2.965

Review 10.  Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer.

Authors:  Ramon Yarza; Mateo Bover; Maria Teresa Agulló-Ortuño; Lara Carmen Iglesias-Docampo
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.